Understanding the Intersection of HHS and Dyslipidemia

Hyperosmolar Hyperglycemic State (HHS) is a life-threatening metabolic emergency most commonly seen in patients with type 2 diabetes. It is characterized by extreme hyperglycemia (often >600 mg/dL), severe dehydration, and altered mental status without significant ketoacidosis. What is less frequently highlighted in clinical discussions is the profound dyslipidemia that accompanies this condition. Lipid abnormalities—including elevated triglycerides, high LDL cholesterol, and low HDL cholesterol—are nearly always present in HHS and pose a significant cardiovascular risk burden that persists long after the acute episode resolves.

Managing these lipid derangements requires more than a conventional approach. The idea of a diabetic lens—a framework that simultaneously addresses glucose control, lipid management, lifestyle factors, and patient-centered goals—has gained traction among endocrinologists and primary care providers. This comprehensive model is critical for reducing the long-term macrovascular complications that plague survivors of HHS, who frequently have multiple coexisting risk factors such as hypertension, obesity, and chronic kidney disease.

An estimated 30–40% of patients admitted for HHS have preexisting cardiovascular disease, and the event itself accelerates atherogenesis through oxidative stress, inflammation, and endothelial injury. Therefore, early and aggressive lipid management is not optional—it is a cornerstone of comprehensive diabetic care in this population. This article provides a detailed, evidence-based guide for healthcare professionals aiming to implement lipid-lowering strategies using the diabetic lens.

Pathophysiology of Dyslipidemia in HHS

To manage lipids effectively, clinicians must first understand why dyslipidemia occurs in HHS. The hallmark of HHS is profound insulin deficiency and resistance, leading to uncontrolled hepatic glucose output and peripheral glucose underutilization. In this state, lipolysis is markedly increased, releasing free fatty acids (FFAs) from adipose tissue into the circulation. The liver subsequently takes up these FFAs and re-esterifies them into very-low-density lipoproteins (VLDL), resulting in hypertriglyceridemia.

Simultaneously, the activity of lipoprotein lipase (LPL), which normally clears triglycerides from the blood, is reduced because insulin is required for LPL synthesis and activation. The net effect is a striking elevation in triglycerides and VLDL particles. HDL cholesterol tends to drop because cholesteryl ester transfer protein (CETP) mediates the exchange of triglycerides from VLDL for cholesterol esters in HDL, rendering HDL particles small and easily cleared. LDL cholesterol may appear normal or only mildly elevated, but LDL particles become small, dense, and more atherogenic.

In the acute setting of HHS, these changes can be profound. Severe hypertriglyceridemia (triglycerides >1,000 mg/dL) may even cause lipemia retinalis or pancreatitis, adding another layer of urgency. Once the acute crisis is managed with fluid resuscitation and insulin therapy, lipid profiles often improve, but they rarely normalize completely. This residual dyslipidemia, combined with ongoing insulin resistance, places patients at persistent high risk for atherosclerotic cardiovascular disease (ASCVD). Therefore, lipid management must extend well beyond the hospital discharge.

Cardiovascular Risks and the Need for Integrated Lipid Management

The relationship between HHS and cardiovascular disease is bidirectional. Not only does HHS worsen existing lipid abnormalities, but the event itself is a marker of poor metabolic control that portends higher future cardiovascular events. Data from registry studies indicate that patients hospitalized for HHS have a two- to threefold higher risk of myocardial infarction, stroke, and cardiovascular death over the next five years compared to matched diabetic controls without HHS.

Moreover, the presence of dyslipidemia in HHS is compounded by other factors common in this population: advanced age, hypertension, albuminuria, and sedentary lifestyle. The American Heart Association (AHA) and the American Diabetes Association (ADA) have long recommended aggressive lipid-lowering targets for individuals with diabetes, particularly those with established ASCVD or high-risk markers. For HHS survivors, the risk is amplified, and many experts argue that these patients should be treated as if they have already had a cardiovascular event—that is, with the same intensity as secondary prevention.

An integrated approach demands that lipid management be woven into the broader diabetes care plan. Isolated treatment of hyperglycemia without addressing LDL cholesterol, triglycerides, or HDL is insufficient. The diabetic lens highlights the synergy between glucose control and lipid improvement: lowering HbA1c reduces VLDL secretion and improves LPL activity, thereby lowering triglycerides and raising HDL. Statins, which are the backbone of lipid pharmacotherapy, also have pleiotropic effects that improve endothelial function and reduce inflammation—beneficial in the hyperglycemic milieu.

The Diabetic Lens for Holistic Lipid Control

The term diabetic lens describes a clinical framework in which every intervention—whether pharmacological, dietary, or behavioral—is evaluated for its impact on both glucose regulation and lipid dynamics. It promotes a shift away from siloed management toward a unified approach that recognizes the interdependence of these metabolic pathways. Using this lens, a clinician might choose a medication that improves both glycemic control and lipid profiles, such as an SGLT2 inhibitor or a GLP-1 receptor agonist, rather than a therapy that addresses only one domain.

This lens also accounts for the fact that lipid goals in HHS patients may differ from those in the general diabetic population. For example, the ADA’s lipid targets include an LDL cholesterol <100 mg/dL (or <70 mg/dL in high-risk patients), triglycerides <150 mg/dL, and non-HDL cholesterol <130 mg/dL. In HHS survivors, the presence of severe hyperglycemia, prior cardiovascular events, or multiple risk factors may push the goal to even more stringent levels. The diabetic lens helps clinicians personalize targets based on the patient’s entire metabolic picture, not just a single lab value.

Core Principles of the Diabetic Lens

  • Concurrent management: Address glucose and lipids simultaneously, not sequentially.
  • Medication synergy: Choose agents that improve both metabolic domains (e.g., GLP-1 RAs, SGLT2 inhibitors, metformin).
  • Lifestyle integration: Diet and exercise plans that optimize glycemic control will naturally improve lipid profiles.
  • Patient engagement: Empower patients to understand how lipid levels relate to their diabetes and overall cardiovascular risk.
  • Longitudinal monitoring: Use repeated assessments to adjust therapy as the patient’s condition evolves.

Implementing this approach requires a deep understanding of the evidence base, as well as the ability to communicate complex concepts to patients in an accessible way. The following sections outline the key strategies that constitute the diabetic lens in practice.

Key Strategies for Managing Lipids in HHS Patients

Lipid Profiling and Risk Stratification

Effective management begins with accurate diagnosis. A fasting lipid panel should be obtained as soon as the patient is stable after HHS resolution, ideally within 48–72 hours of admission. However, because lipids can be depressed during acute illness, a repeat panel 4–6 weeks after discharge is essential to establish baseline values. The panel should include total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and non-HDL cholesterol. Apolipoprotein B or LDL particle number may provide additional risk information in patients with hypertriglyceridemia or metabolic syndrome, but these are not universally available.

Risk stratification tools such as the ASCVD Risk Estimator from the AHA should be used to determine the intensity of therapy required. For HHS patients, the presence of severe hyperglycemia, long diabetes duration, or prior cardiovascular events automatically places them in the high-risk or very-high-risk category. In such patients, the target for LDL is <70 mg/dL, and for non-HDL cholesterol it is <100 mg/dL. Triglycerides should be <150 mg/dL, and if fasting values exceed 500 mg/dL, the risk of pancreatitis becomes a priority and may require fibrates or high-dose omega-3 fatty acids.

Dietary Interventions

Nutrition therapy is the foundation of the diabetic lens. A heart-healthy diet that emphasizes whole grains, lean proteins, unsaturated fats, and ample fiber can lower LDL and triglycerides while improving glycemic control. For HHS patients, the Dietary Approaches to Stop Hypertension (DASH) pattern or a Mediterranean-style diet are particularly suitable. These diets are rich in omega-3 fatty acids from fish, nuts, and seeds, and they limit added sugars, refined carbohydrates, and trans fats.

Reducing carbohydrate intake to 40–50% of total calories often helps lower postprandial glucose and triglyceride levels. For patients with severe hypertriglyceridemia (triglycerides >1,000 mg/dL), an extremely low-fat diet (less than 20% of calories from fat) may be needed temporarily, along with aggressive pharmacological intervention. A registered dietitian with expertise in diabetes should be part of the team to tailor meal plans to cultural preferences, renal function, and other comorbidities.

Physical Activity and Weight Management

Exercise improves insulin sensitivity, reduces VLDL production, and raises HDL cholesterol. Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, complemented by resistance training twice weekly. For patients who have recently experienced HHS, it is crucial to start slowly—typically with walking or stationary cycling—and gradually increase intensity once blood glucose is stable and hydration is adequate. Weight loss of 5–10% of body weight in overweight or obese patients significantly improves both lipids and glycemia, and bariatric surgery may be considered in eligible individuals with BMI >35 kg/m².

Pharmacotherapy

Statins

Statins (HMG-CoA reductase inhibitors) are first-line therapy for LDL cholesterol reduction in HHS patients. Atorvastatin 40–80 mg or rosuvastatin 20–40 mg are preferred in high-risk individuals. Statins have been shown to reduce cardiovascular events by 25–40% in patients with diabetes, and they also modestly lower triglycerides (by 20–30%) and raise HDL slightly. Importantly, statins do not worsen glycemic control—though high-dose statins may increase HbA1c by 0.1–0.3%, this effect is far outweighed by cardiovascular benefit. In HHS, initiating a moderate- or high-intensity statin at discharge is standard.

Fibrates

Fibrates (e.g., fenofibrate, gemfibrozil) primarily lower triglycerides and raise HDL. They are particularly useful when triglycerides remain above 200–500 mg/dL despite statin therapy and lifestyle changes. The combination of a statin plus fenofibrate has been studied in diabetes, with some trials showing reductions in nonfatal myocardial infarction, though overall ASCVD benefit may be limited. Fenofibrate is preferred over gemfibrozil when combined with statins because of a lower risk of myopathy. Fibrates should be used cautiously in patients with renal impairment, which is common in HHS patients.

Omega-3 Fatty Acids

Prescription omega-3 ethyl esters (icosapent ethyl, at 4 g/day) have been shown to reduce cardiovascular events in patients with elevated triglycerides (135–499 mg/dL) despite statin therapy, as demonstrated in the REDUCE-IT trial. This may be a valuable addition for HHS patients with persistent hypertriglyceridemia. Omega-3s do not significantly affect LDL but can lower triglycerides by 20–30%. Non-prescription fish oil supplements are not recommended due to inconsistent quality and dosing.

Ezetimibe and PCSK9 Inhibitors

For patients who do not achieve LDL targets on statin therapy alone, ezetimibe 10 mg daily can provide an additional 15–20% reduction. In high-risk patients, the IMPROVE-IT trial showed that adding ezetimibe to simvastatin reduced cardiovascular events. For those with LDL >190 mg/dL, familial hypercholesterolemia, or statin intolerance, PCSK9 inhibitors (evolocumab, alirocumab) can be used. These agents reduce LDL by 50–60% and have also shown cardiovascular benefit in patients with diabetes. However, their high cost and injectable route limit widespread use in the HHS population unless specifically indicated.

Glycemic Control

Optimizing blood glucose is a direct lipid-lowering intervention. Insulin therapy, which is standard in acute HHS management, effectively reduces FFAs and triglycerides. Once the patient is stabilized, transitioning to a diabetes regimen that includes an SGLT2 inhibitor or GLP-1 receptor agonist can provide dual benefits. SGLT2 inhibitors (e.g., empagliflozin) lower major adverse cardiovascular events and reduce weight, which improves lipid profiles. GLP-1 RAs (e.g., liraglutide, semaglutide) reduce triglycerides, modestly lower LDL, and improve HDL. Metformin, if tolerated, is also a safe option with neutral or beneficial effects on lipids.

It is important to avoid medications that worsen dyslipidemia. Thiazolidinediones (TZDs) raise LDL cholesterol, and some sulfonylureas and insulin in high doses may promote weight gain and hypertriglyceridemia. The diabetic lens guides the prescriber toward agents that harmonize glucose and lipid goals.

Multidisciplinary Care and Patient Education

Managing lipid levels in HHS patients is too complex for any single provider to handle alone. A multidisciplinary team should include an endocrinologist, a primary care physician, a dietitian, a diabetes educator, and a pharmacist. Each member plays a specific role: the endocrinologist oversees the medication regimen, the dietitian tailors nutrition, the educator reinforces lifestyle and monitoring, and the pharmacist checks for drug interactions (e.g., statin interactions with macrolide antibiotics or azole antifungals).

Patient education is paramount. Many HHS survivors do not fully understand that their lipid levels are as important as their blood sugar. Using plain language and visual aids, clinicians should explain the concept of hardened arteries, how high cholesterol causes blockages, and why lowering LDL can prevent heart attack and stroke. It is also essential to address barriers such as medication cost, fear of injections, or confusion about food labels. Shared decision-making—where the patient’s values and preferences are integrated into the care plan—improves adherence and outcomes.

Follow-up schedules should include visits at 4–6 weeks post-discharge for a lipid panel, then every 3–6 months for the first year. After stabilization, annual lipid panels are acceptable unless changes in therapy or clinical status warrant more frequent checks. Each visit should be an opportunity to reinforce the diabetic lens, review adherence, and adjust medications as needed.

Monitoring Lipid Levels and Adjusting Therapy

Monitoring is not a one-time event. It is a dynamic process that reveals how well the integrated strategy is working. After the baseline lipid panel at 4–6 weeks, the next assessment should occur 3–6 months after starting or adjusting lipid-lowering therapy. At that point, the clinician can determine if targets are being met. If not, intensification of therapy—by increasing statin dose, adding ezetimibe, or considering a PCSK9 inhibitor—should be considered.

Special attention should be paid to triglycerides. If fasting triglycerides remain above 500 mg/dL despite treatment, consider adding a fibrate or high-dose omega-3. Also, evaluate for secondary causes of hypertriglyceridemia, such as hypothyroidism, nephrotic syndrome, excess alcohol intake, or poorly controlled diabetes itself. Addressing these underlying factors can dramatically improve lipid values.

LDL cholesterol trends are the primary outcome measure for statin therapy. If LDL is not reduced by at least 50% from baseline (or below 70 mg/dL in very-high-risk patients), therapy escalation is warranted. Non-HDL cholesterol, which includes all atherogenic particles, is a secondary target. Monitoring liver enzymes and muscle symptoms is appropriate when using statins, especially at high doses or in combination with fibrates.

Special Considerations in HHS Patients

HHS patients often present with acute kidney injury (AKI) due to dehydration. This affects clearance of medications such as fenofibrate and some statins. For example, lovastatin and simvastatin are not recommended in patients with significant renal impairment; atorvastatin and rosuvastatin can be used with caution and dose adjustment. Additionally, patients may be on multiple medications (antihypertensives, antiplatelet agents, SGLT2 inhibitors) that interact with lipid drugs. A thorough medication review is necessary at every visit.

The acute phase of HHS also involves electrolyte disturbances, particularly hypernatremia and hypokalemia or hypomagnesemia. Correcting these imbalances before initiating certain lipid-lowering therapies (such as fibrates, which can increase creatinine) is prudent. Furthermore, patients with HHS are often elderly and may have geriatric syndromes such as frailty or cognitive impairment, which complicate adherence to complex medication regimens. Simplified dosing schedules (e.g., fixed-dose combinations, once-daily agents) can improve outcomes.

Emerging Therapies and Innovations

Newer therapies continue to expand the armamentarium for lipid management in diabetes. Inclisiran, a small interfering RNA that reduces PCSK9 production, provides twice-yearly subcutaneous injections and has shown powerful LDL reduction. Bempedoic acid, an ATP-citrate lyase inhibitor, offers a non-statin alternative for patients with statin intolerance. While not yet widely approved for use in diabetic emergencies, these agents hold promise for long-term maintenance therapy in HHS survivors.

In addition, the role of inflammation in dyslipidemia is becoming clearer. Studies of canakinumab, an anti-inflammatory antibody, showed reduced cardiovascular events in patients with elevated CRP, independent of lipid levels. Although not currently recommended for lipid management, this highlights the potential for future treatments that target the immune-metabolic interface. Clinical trials are ongoing to evaluate whether combination lipid therapy with novel agents can further reduce the residual risk seen in patients with diabetes and prior HHS.

Conclusion

Managing lipid levels in patients who have experienced HHS is an urgent clinical priority that demands a comprehensive, integrated approach. The diabetic lens provides a powerful conceptual framework that aligns glucose control, lipid management, lifestyle optimization, and patient engagement into a single coherent strategy. By understanding the pathophysiology of dyslipidemia in HHS and by implementing evidence-based pharmacological and non-pharmacological interventions, healthcare teams can significantly reduce the high cardiovascular risk that characterizes this population.

Regular monitoring, multidisciplinary collaboration, and a commitment to personalized care are essential. The goal is not merely to achieve numeric targets on a lab report, but to improve long-term outcomes—fewer heart attacks, fewer strokes, and better quality of life. For clinicians caring for these complex patients, every decision made through the diabetic lens brings better hope for comprehensive cardiovascular protection.

For further reading: